Castlight8knovember242014
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934
November 24, 2014
Date of Report (Date of earliest event reported)
CASTLIGHT HEALTH, INC.
(Exact name of registrant as specified in its charter)
______________________________________
|
| | |
|
| | |
Delaware (State or other jurisdiction of incorporation or organization) | 001-36330
(Commission File Number) | 26-1989091 (I.R.S. Employer Identification Number) |
______________________________________
Two Rincon Center
121 Spear Street, Suite 300
San Francisco, CA 94105
(Address of principal executive offices)
(415) 829-1400
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions :
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
______________________________________
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Directors.
(b)
On November 24, 2014, Dena Bravata, the Company’s Chief Medical Officer and Head of Products, provided notice to the Company of her intention to resign, effective December 31, 2014, to pursue other opportunities. Until December 31, 2014, Dr. Bravata will continue to provide services to the Company to assist in the transition of her responsibilities to other members of the Company’s management team.
(e)
In connection with Dr. Bravata’s resignation from the office of Chief Medical Officer and Head of Products, on November 24, 2014, the Company agreed to provide the following benefits to Dr. Bravata: (i) a lump sum payment of $129,000, equivalent to Dr. Bravata’s base salary for six months, (ii) COBRA coverage for her applicable benefits for a six-month period, and (iii) acceleration of the vesting of Dr. Bravata’s outstanding stock options under the Company’s equity incentive plans through June 30, 2015. In addition, Dr. Bravata is eligible to receive her bonus payment for services rendered during 2014 in accordance with the Company’s standard bonus practices. In return, Dr. Bravata agreed to standard terms such as a release of any claims, agreements relating to confidentiality, non-solicitation of Company employees, and other related matters.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Castlight Health Inc.
Date: November 24, 2014
By: /s/ John C. Doyle
John C. Doyle
Chief Financial Officer